BBC vs. LFSC

Last updated Jun 3, 2026

BBC (Virtus LifeSci Biotech Clinical Trials ETF) and LFSC (F/m Emerald Life Sciences Innovation ETF) are both Health & Biotech Equities funds. BBC is passively managed, while LFSC is actively managed. Over the past year, BBC returned 123.11% vs 60.36% for LFSC. Their correlation of 0.81 suggests significant overlap in exposure. BBC charges 0.79%/yr vs 0.54%/yr for LFSC.

Performance

BBC vs. LFSC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Virtus LifeSci Biotech Clinical Trials ETF (BBC) and F/m Emerald Life Sciences Innovation ETF (LFSC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BBC achieves a 8.17% return, which is significantly higher than LFSC's 2.73% return.

BBC

• 1D: -4.90%
• 1M: -4.81%
• YTD: 8.17%
• 6M: 20.12%
• 1Y: 123.11%
• 3Y*: 19.82%
• 5Y*: -2.05%
• 10Y*: 7.60%

LFSC

• 1D: -2.62%
• 1M: -1.41%
• YTD: 2.73%
• 6M: 2.87%
• 1Y: 60.36%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

BBC vs. LFSC - Yearly Performance Comparison

	2026 (YTD)	2025	2024
BBC Virtus LifeSci Biotech Clinical Trials ETF	8.17%	63.77%	-14.94%
LFSC F/m Emerald Life Sciences Innovation ETF	2.73%	56.54%	-6.02%

Correlation

The correlation between BBC and LFSC is 0.80, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.80
Correlation (All Time) Calculated using the full available price history since Nov 1, 2024	0.81

The correlation between BBC and LFSC has been stable across timeframes, ranging from 0.80 to 0.81 - a consistent structural relationship.

Return for Risk

BBC vs. LFSC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBC

BBC Risk / Return Rank: 90
BBC Sharpe Ratio Rank: 93
BBC Sortino Ratio Rank: 89
BBC Omega Ratio Rank: 79
BBC Calmar Ratio Rank: 96
BBC Martin Ratio Rank: 94

LFSC

LFSC Risk / Return Rank: 68
LFSC Sharpe Ratio Rank: 69
LFSC Sortino Ratio Rank: 70
LFSC Omega Ratio Rank: 62
LFSC Calmar Ratio Rank: 76
LFSC Martin Ratio Rank: 61

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBC vs. LFSC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Clinical Trials ETF (BBC) and F/m Emerald Life Sciences Innovation ETF (LFSC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BBC	LFSC	Difference
Sharpe ratio Return per unit of total volatility	3.49	2.33	+1.15
Sortino ratio Return per unit of downside risk	4.11	3.25	+0.86
Omega ratio Gain probability vs. loss probability	1.48	1.38	+0.09
Calmar ratio Return relative to maximum drawdown	8.82	3.94	+4.88
Martin ratio Return relative to average drawdown	28.55	11.02	+17.53
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BBC vs. LFSC - Sharpe Ratio Comparison

The current BBC Sharpe Ratio is 3.49, which is higher than the LFSC Sharpe Ratio of 2.33. The chart below compares the historical Sharpe Ratios of BBC and LFSC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	BBC	LFSC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.49	2.33	+1.15
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.05	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.20	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.12	1.04	-0.93

Drawdowns

BBC vs. LFSC - Drawdown Comparison

The maximum BBC drawdown since its inception was -76.85%, which is greater than LFSC's maximum drawdown of -29.74%. Use the drawdown chart below to compare losses from any high point for BBC and LFSC.

Drawdown Indicators

	BBC	LFSC	Difference
Max Drawdown Largest peak-to-trough decline	-76.85%	-29.74%	-47.11%
Max Drawdown (1Y) Largest decline over 1 year	-15.10%	-16.25%	+1.15%
Max Drawdown (3Y) Largest decline over 3 years	-54.45%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-72.44%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-76.85%	—	—
Current Drawdown Current decline from peak	-30.57%	-4.60%	-25.97%
Average Drawdown Average peak-to-trough decline	-37.14%	-7.83%	-29.31%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.66%	5.81%	-1.15%

Volatility

BBC vs. LFSC - Volatility Comparison

Virtus LifeSci Biotech Clinical Trials ETF (BBC) has a higher volatility of 11.21% compared to F/m Emerald Life Sciences Innovation ETF (LFSC) at 7.47%. This indicates that BBC's price experiences larger fluctuations and is considered to be riskier than LFSC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BBC	LFSC	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.21%	7.47%	+3.74%
Volatility (6M) Calculated over the trailing 6-month period	26.65%	18.58%	+8.07%
Volatility (1Y) Calculated over the trailing 1-year period	35.74%	26.08%	+9.66%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	39.31%	28.92%	+10.39%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	37.75%	28.92%	+8.83%

BBC vs. LFSC - Expense Ratio Comparison

BBC has a 0.79% expense ratio, which is higher than LFSC's 0.54% expense ratio.

Dividends

BBC vs. LFSC - Dividend Comparison

BBC's dividend yield for the trailing twelve months is around 1.57%, while LFSC has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BBC Virtus LifeSci Biotech Clinical Trials ETF	1.57%	1.70%	1.00%	0.34%	0.00%	0.00%	0.00%	0.00%	0.00%	2.09%	0.00%	0.51%
LFSC F/m Emerald Life Sciences Innovation ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both BBC and LFSC in my portfolio?

BBC and LFSC have a correlation of 0.80, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BBC or LFSC?

BBC has higher volatility (11.21%) compared to LFSC (7.47%). In terms of maximum drawdown, BBC dropped -76.85% vs LFSC's -29.74%.

Which ETF is better, BBC or LFSC?

On 1-year performance, BBC leads with 123.11% vs 60.36% for LFSC. On fees, LFSC is cheaper at 0.54% per year. On volatility, LFSC has been the lower-risk option at 7.47%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, BBC or LFSC?

Over the 1-year period, BBC has performed better with a 123.11% return vs 60.36%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, BBC or LFSC?

LFSC is cheaper with a 0.54% expense ratio, compared with 0.79% for BBC.

Which ETF pays a higher dividend yield, BBC or LFSC?

BBC has the higher dividend yield at 1.57%, compared with 0.00% for LFSC.

What is the main difference between BBC and LFSC?

They also come from different issuers: Virtus Investment Partners and F/m Investments. Their fees differ too: 0.79% for BBC and 0.54% for LFSC.

Which has better risk-adjusted returns?

BBC currently has the higher Sharpe Ratio (3.49 vs 2.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.